The endocannabinoid ARA-S acts as an endogenous rescuing factor of Kv7.1/KCNE1 carrying Long QT syndrome mutations and paves the way for drug development strategies

I Hiniesto Inigo,A Sridhar,S A Lundholm,S I Liin

DOI: https://doi.org/10.1093/cvr/cvae088.021

IF: 13.081

2024-05-31

Cardiovascular Research

Abstract:Funding Acknowledgements Type of funding sources: Public grant(s) – EU funding. Main funding source(s): European Union's Horizon 2020 research and innovation program Long QT Syndrome (LQTS) is a cardiac arrhythmia characterized by delayed ventricular repolarization. LQTS occurs when there are loss-of-function mutations in genes encoding for voltage-gated channels and their beta subunits that contribute to the cardiac action potential. Among them, the most mutated channel is Kv7.1/KCNE1, which encodes for the slowly activating component of the delayed rectifier K+ current (IKs). Families with inherited mutations in the Kv7.1/KCNE1 exhibit inconsistent correlations between genotypes and phenotypes making the clinical management of LQTS challenging. A possible strategy to help guide clinical approaches involves exploring endogenous compounds capable of modulating the Kv7.1/KCNE1 channel function, acting as potential disease modifiers. Using the two-electrode voltage clamp technique, we previously found that the endogenous endocannabinoid-like compound ARA-S, which has an arachidonic acid tail and a serine head group, facilitates activation of the wild-type Kv7.1/KCNE1 channel expressed in Xenopus oocytes. This is seen as a left shift in the voltage dependence of channel opening and an increase in conductance. Moreover, we showed that ARA-S restores a physiological QT interval in isolated guinea pig hearts suffering from drug-induced LQTS. Hence, ARA-S is an interesting endogenous Kv7.1/KCNE1 channel modulator that may influence disease severity. However, it is uncertain whether ARA-S also activates the Kv7.1/KCNE1 when it carries LQTS-associated mutations. Therefore, the current study involves studying the effect of ARA-S on mutated Kv7.1/KCNE1 channels using two-electrode voltage clamp electrophysiology. We find that ARA-S facilitates the activation of all tested LQTS mutants. However, the magnitude of the effect varies among them, suggesting that the compound ́s effect is dependent on the genetic background. To understand why ARA-S has different effects, we use computational simulation approaches to study how mutations in the putative ARA-S binding sites change ARA-S efficacy. This understanding aids in developing new substances that can activate different mutations, by, for example, modifying the ARA-S tail to enhance its efficacy. We also try to understand the concentration of ARA-S required to restore a wild-type-like function of each mutant, considering the mutant's intrinsic behavior and the apparent affinity of ARA-S for the specific mutant. Altogether, this work finds ARA-S to be an efficient activator of LQTS-associated mutant Kv7.1/KCNE1 channels and is a first step towards understanding how the genetic background determines the effect of this endogenous modulator.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

This paper aims to solve the problem of functional restoration of the mutated Kv7.1/KCNE1 channels in Long QT Syndrome (LQTS). Specifically, the researchers explored the effect of the endogenous compound ARA - S on the Kv7.1/KCNE1 channels carrying LQTS - related mutations. LQTS is a heart disease characterized by delayed ventricular repolarization, which is usually caused by loss - of - function mutations in genes encoding voltage - gated channels and their β - subunits. Kv7.1/KCNE1 is one of the most frequently mutated channels in this category and is responsible for the slowly activating delayed rectifier potassium current (\(I_{Ks}\)). However, families carrying these mutations show inconsistent correlations between genotype and phenotype, which complicates the clinical management of LQTS. The main questions of the study were to determine whether ARA - S could activate the Kv7.1/KCNE1 channels with LQTS - related mutations and to evaluate whether the magnitude of this activation effect varies with different genetic backgrounds. Using the two - electrode voltage - clamp technique, the researchers found that ARA - S can indeed promote the activation of all tested LQTS mutants, but there are differences in the strength of the effect among different mutants. To further understand these differences, the researchers also used computational simulation methods to study how mutations change the ARA - S binding sites, thereby affecting the efficacy of ARA - S. In addition, they also attempted to determine the concentration of ARA - S required to restore the wild - type - like function of each mutant, taking into account the intrinsic behavior of the mutant and the apparent affinity of ARA - S for this specific mutation. In summary, this work not only confirms ARA - S as an effective activator of Kv7.1/KCNE1 channels with LQTS - related mutations, but also lays the foundation for further understanding how genetic backgrounds determine the effect of this endogenous regulator, providing a theoretical basis for the development of new substances for different mutations.

The endocannabinoid ARA-S acts as an endogenous rescuing factor of Kv7.1/KCNE1 carrying Long QT syndrome mutations and paves the way for drug development strategies

The endocannabinoid ARA-S facilitates the activation of cardiac Kv7.1/KCNE1 channels from different species

Molecular Insights into the Rescue Mechanism of an hERG Activator Against Severe LQT2 Mutations.

Pharmacological Activation of Normal and Arrhythmia-Associated Mutant KCNQ1 Potassium Channels

The electrophysiologic effects of KCNQ1 extend beyond expression of I Ks: evidence from genetic and pharmacologic block

Efficacy and safety of HERG channel agonists for treatment of Long QT Syndrome type 8

Mutations In Cytoplasmic Loops Of The Kcnq1 Channel And The Risk Of Life-Threatening Events Implications For Mutation-Specific Response To Beta-Blocker Therapy In Type 1 Long-Qt Syndrome

Targeting the IKs Channel PKA Phosphorylation Axis to Restore Its Function in High-Risk LQT1 Variants

SGK1 inhibition normalizes action potential duration in transgenic LQT2 rabbits but not in LQT1, suggesting a novel gene-specific therapeutic approach in long QT syndrome

Pharmacological activation of the hERG K+ channel for the management of the long QT syndrome: A review

RNA interference targeting E637K mutation rescues hERG channel currents and restores its kinetic properties

The Human Ether-A-Go-Go–Related Gene Activator NS1643 Enhances Epilepsy-Associated KCNQ Channels

Beneficial normalization of cardiac repolarization by carnitine in transgenic SQT1 rabbit models

Development of new Kir2.1 channel openers from propafenone analogues

Biochemical, biophysical, and structural investigations of two mutants (C154Y and R312H) of the human Kir2.1 channel involved in the Andersen-Tawil syndrome.

The Kir2.1E299V mutation increases atrial fibrillation vulnerability while protecting the ventricles against arrhythmias in a mouse model of Short QT Syndrome type 3

Computational Analysis of the Effects of KCNJ2-linked E299V Mutation Short QT Syndrome and Its Potential Therapeutic Targets

The fully activated open state of KCNQ1 controls the cardiac 'fight-or-flight' response

A Molecular Mechanism for Adrenergic-Induced Long QT Syndrome.

Computational insights into the mechanisms underlying structural destabilization and recovery in trafficking-deficient hERG mutants

Novel Gain-of-Function Mutation in the Kv11.1 Channel Found in the Patient with Brugada Syndrome and Mild QTc Shortening